Provided by Tiger Trade Technology Pte. Ltd.

Enanta Pharmaceuticals

13.18
+0.54004.27%
Pre-market: 13.180.00000.00%08:19 EDT
Volume:425.88K
Turnover:5.61M
Market Cap:382.46M
PE:-5.63
High:13.41
Open:12.67
Low:12.44
Close:12.64
52wk High:17.15
52wk Low:9.91
Shares:29.02M
Float Shares:22.51M
Volume Ratio:1.64
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3416
EPS(LYR):-3.8381
ROE:-70.12%
ROA:-12.28%
PB:3.78
PE(LYR):-3.43

Loading ...

Enanta FY26 Q2 net loss narrows to $13.1 million; revenue rises to $17.2 million

Reuters
·
May 12

BRIEF-Enanta Pharmaceuticals Q2 Revenue USD 17.159 Million Vs. IBES Estimate USD 17.1 Million

Reuters
·
May 12

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Second Quarter Ended March 31, 2026

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc - Expects Cash Runway to Fund Operations Into Fiscal 2029

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Q2 Pretax Profit USD -13.084 Million

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc - on Track to File Ind for EPS-3903 and Select Mrgprx2 Candidate in 2H 2026

THOMSON REUTERS
·
May 12

Enanta Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
May 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

Enanta says Phase 2 trial shows zelicapavir reduces RSV symptom duration, hospitalization

Reuters
·
May 04

Enanta announces first participant dosed in Phase 1 trial of EDP-978

TIPRANKS
·
Apr 13

Enanta doses first participant in Phase 1 trial of urticaria drug EDP-978

Reuters
·
Apr 13

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of Edp-978, an Oral, Once-Daily Kit Inhibitor, in Development for the Treatment of Urticaria

THOMSON REUTERS
·
Apr 13

Enanta Pharmaceuticals Inc - Topline Data Expected in Q4 2026

THOMSON REUTERS
·
Apr 13

Enanta to present Phase 2b zelicapavir RSV trial data at ESCMID Global 2026

Reuters
·
Apr 07

Top Premarket Decliners

MT Newswires Live
·
Apr 06

Enanta to present preclinical data on oral STAT6 inhibitor EPS-3903 at IMMUNOLOGY2026

Reuters
·
Mar 30